A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma
The purpose of this study is the area under the curve (AUC) for GB241 and rituximab concentrations.
B-Cell Lymphoma
BIOLOGICAL: GB241|BIOLOGICAL: Rituximab
Area under the curve (AUC) for GB241 and rituximab concentrations, 85 days
AUC for GB241 and rituximab concentrations, 1 week, 2 weeks, 4 weeks, 8 weeks and 12 weeks|Maximum observed concentration of the GB241 and rituximab, 85 days|Degree of clearance from baseline of CD19+ , CD20+ B-cells between the two study arms, 85 days|Comparison of AEs between the two study arms, 85 days|Comparison of the incidence rate of HACA（host anti-chimeric antibody） between the two study arms, 85 days
The purpose of this study is the area under the curve (AUC) for GB241 and rituximab concentrations.